drug_type
RELEVANT_DRUG
intervention_type
Radiopharmaceutical (therapeutic)
drug_description
An anti-PSMA IgG monoclonal antibody conjugated with the tetraxetan chelator and radiolabeled with actinium-225; a targeted alpha therapy delivering high-LET alpha emissions to PSMA-expressing tumor cells, causing DNA double-strand breaks and tumor cell death.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Actinium
drug_category
RADIOIMMUNOCONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
Anti-PSMA IgG monoclonal antibody chelated with tetraxetan delivers actinium-225 to PSMA-expressing tumor cells. The Ac-225 emits high-LET alpha particles that induce localized DNA double-strand breaks, leading to targeted cytotoxicity and tumor cell death.
drug_name
Ac-225 rosopatamab tetraxetan
nct_id_drug_ref
NCT06549465